文献速递中毒与环境急症消化、代谢与肾脏急症

2019-2022年美国各州过量死亡与法医药物报告中的赛拉嗪

Xylazine in Overdose Deaths and Forensic Drug Reports in US States, 2019-2022.
PubMed 文献 · JAMA Netw Open · 2024-01-02
一句话结论2019-2022年美国至少43州报告过赛拉嗪相关过量死亡,但仅21州有年度死亡数,数据覆盖不足半数州。

该横断面研究二次分析了2019至2022年国家法医实验室信息系统(NFLIS)、国家卫生统计中心及各州法医或公共卫生机构报告的数据,评估各州赛拉嗪相关过量死亡率和NFLIS药物报告占比。死亡分析纳入63个州-年,NFLIS报告分析纳入204个州-年;至少43州报告过至少1例赛拉嗪相关过量死亡,但仅21州有年度死亡数。2022年佛蒙特州(10.5/10万)和康涅狄格州(9.8/10万)死亡率最高;德拉瓦州赛拉嗪占NFLIS报告16.17%,康涅狄格、马里兰、哥伦比亚特区、新泽西和罗德岛为5.95%-7.00%,但35州不足1.0%。赛拉嗪报告集中在美国东部但已遍及全国,州级死亡数据公开不足阻碍公共卫生应对。

要点

  • 2019-2022年至少43州报告过至少1例赛拉嗪相关过量死亡,但年度死亡数仅21州公开可用。
  • 2022年赛拉嗪相关过量死亡率最高为佛蒙特州10.5/10万和康涅狄格州9.8/10万。
  • 2022年德拉瓦州赛拉嗪占NFLIS药物报告16.17%,康涅狄格、马里兰、哥伦比亚特区、新泽西和罗德岛为5.95%-7.00%,35州不足1.0%。
  • 2019年16州NFLIS报告中无赛拉嗪记录,2022年仅2州为零,除3州外所有州赛拉嗪占比均上升。
  • 赛拉嗪报告集中在美国东部但已遍及全国,州级年度死亡数据不足半数州,妨碍本地公共卫生应对。

适用人群与场景

  • 2019至2022年美国各州过量死亡者及执法部门查获、经NFLIS参与实验室分析的药物样本。

研究设计与关键结果

  • 横断面研究二次分析2019至2022年NFLIS、国家卫生统计中心及各州法医或公共卫生机构报告数据,数据分析于2023年8月至10月进行。
  • 死亡分析纳入63个州-年,NFLIS报告分析纳入204个州-年。
  • 至少43州报告过至少1例赛拉嗪相关过量死亡,但年度赛拉嗪相关死亡总数仅21州可用。
  • 有数据州中,2022年赛拉嗪相关过量死亡率最高为佛蒙特州10.5/10万居民和康涅狄格州9.8/10万居民。
  • 2019年16州NFLIS报告中赛拉嗪报告为零,2022年仅2州为零,除3州外所有州赛拉嗪在NFLIS报告中的占比均上升。
  • 2022年德拉瓦州赛拉嗪占全部NFLIS报告的16.17%,康涅狄格、马里兰、哥伦比亚特区、新泽西和罗德岛为5.95%至7.00%,但35个不同州不足1.0%。

证据类型、等级与局限

  • 证据类型:横断面研究(二次分析公开数据)。
  • 局限:年度州级赛拉嗪相关过量死亡数仅不到半数州公开可用。

对床旁实践的改变

  • 作者认为,赛拉嗪在过量死亡和法医报告中的报告存在集中在美国东部但已遍及全国,而州级年度死亡数据仅不到半数州公开可用,妨碍本地公共卫生应对。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Xylazine is increasingly reported in street drugs and fatal overdoses in the US, yet state-level data are limited, hampering local public health responses.

OBJECTIVE: To gather available state-level data on xylazine involvement in overdose deaths and in forensic drug reports.

DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional study was a secondary analysis of 2019 to 2022 data from the National Forensic Laboratory Information System (NFLIS), National Center for Health Statistics, and individual states' medical examiner or public health agency reports. Data were analyzed from August to October 2023.

MAIN OUTCOMES AND MEASURES: Yearly xylazine-related overdose deaths per 100 000 residents; xylazine NFLIS drug reports, both per 100 000 residents and as a percentage of all NFLIS drug reports (from samples of drugs seized by law enforcement and analyzed by NFLIS-participating laboratories).

RESULTS: A total of 63 state-years were included in analyses of mortality rates, while 204 state-years were included in analyses of NFLIS reports. According to the publicly available data compiled in this study, at least 43 states reported at least 1 xylazine-related overdose death from 2019 to 2022, yet yearly totals of xylazine-related deaths were available for only 21 states. Of states with data available, xylazine-involved overdose death rates were highest in Vermont (10.5 per 100 000 residents) and Connecticut (9.8 per 100 000 residents) in 2022. In 2019, 16 states had zero xylazine reports included in NFLIS reports; in 2022, only 2 states had zero xylazine reports and all but 3 states had recorded an increase in xylazine's representation in NFLIS reports. In 2022, xylazine represented 16.17% of all NFLIS reports in Delaware and between 5.95% and 7.00% of NFLIS reports in Connecticut, Maryland, District of Columbia, New Jersey, and Rhode Island, yet less than 1.0% of NFLIS reports in 35 different states.

CONCLUSIONS AND RELEVANCE: In this cross-sectional study of publicly available data on fatal overdoses and drugs analyzed by forensic laboratories, xylazine's reported presence in overdose deaths and forensic reports was concentrated in the eastern US yet extended across the country to encompass nearly all states. In spite of xylazine's geographic reach, yearly state-level numbers of xylazine-related overdose deaths were publicly available for less than half of all states.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Cano M, Daniulaityte R, Marsiglia F, et al. Xylazine in Overdose Deaths and Forensic Drug Reports in US States, 2019-2022. JAMA Netw Open. 2024. PMID: 38180756. doi:10.1001/jamanetworkopen.2023.50630

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。